

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 November 2020 (26.11.2020)



(10) International Publication Number
WO 2020/235665 A1

(51) International Patent Classification:

C07D 207/12 (2006.01) A61P 17/00 (2006.01)
A61K 31/4015 (2006.01) A61P 43/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/JP2020/020210

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

22 May 2020 (22.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/851,880 23 May 2019 (23.05.2019) US

(71) Applicants: KAKEN PHARMACEUTICAL CO., LTD.

[JP/JP]; 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo,
1138650 (JP). BRICKELL BIOTECH, INC. [US/US];
5777 Central Avenue, Suite 102, Boulder, Colorado, 80301
(US).

(72) Inventors: MARUBAYASHI Kazuyoshi; c/o KAKEN

PHARMACEUTICAL CO., LTD., 301, Gensuke, Fujie-
da-shi, Shizuoka, 4268646 (JP). WATANABE Masahito;
c/o KAKEN PHARMACEUTICAL CO., LTD., 301, Gen-
suke, Fujieda-shi, Shizuoka, 4268646 (JP). BRINKMAN
Herbert R.; 3439 Golden Currant Blvd., Fort Collins, Col-
orado, 80521 (US).

(74) Agent: SIKS & CO.; 8th Floor, Kyobashi-Nisshoku Bldg.,

8-7, Kyobashi 1-chome, Chuo-ku, Tokyo, 1040031 (JP).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF

(57) Abstract: A cocrystal containing the 1'R-diastereomer and the 1'S-diastereomer of sofipironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1'R-diastereomer (Form MN), and a method for preparing sofipironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofipironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.



WO 2020/235665 A1